Health Care [ 4/12 ] | Pharmaceuticals [ 14/72 ]
NYSE | Common Stock
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide.
It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.
The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer.
It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis.
The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance.
Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis.
The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; Foghorn Therapeutics Inc., and PRISM BioLab Co.,Ltd. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 6, 24 | 2.58 Increased by +59.26% | 2.46 Increased by +4.88% |
| Mar 6, 24 | 2.49 Increased by +19.14% | 2.22 Increased by +12.16% |
| Nov 2, 23 | 0.10 Decreased by -94.95% | -0.13 Increased by +176.92% |
| Aug 8, 23 | 2.11 Increased by +68.80% | 1.98 Increased by +6.57% |
| Apr 27, 23 | 1.62 Decreased by -41.52% | 1.73 Decreased by -6.36% |
| Feb 2, 23 | 2.09 Decreased by -16.06% | 1.78 Increased by +17.42% |
| Nov 1, 22 | 1.98 Increased by +2.06% | 1.92 Increased by +3.13% |
| Aug 4, 22 | 1.25 Decreased by -33.16% | 1.69 Decreased by -26.04% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 9.50 B Increased by +36.84% | -57.40 M Decreased by -103.95% | Decreased by -0.60% Decreased by -102.89% |
| Jun 30, 23 | 8.31 B Increased by +28.11% | 1.76 B Increased by +85.11% | Increased by +21.21% Increased by +44.49% |
| Mar 31, 23 | 6.96 B Decreased by -10.88% | 1.34 B Decreased by -29.32% | Increased by +19.32% Decreased by -20.69% |
| Dec 31, 22 | 7.30 B Decreased by -8.73% | 1.94 B Increased by +12.26% | Increased by +26.54% Increased by +22.99% |
| Sep 30, 22 | 6.94 B Increased by +2.49% | 1.45 B Increased by +30.77% | Increased by +20.91% Increased by +27.59% |
| Jun 30, 22 | 6.49 B Decreased by -3.74% | 952.50 M Decreased by -31.48% | Increased by +14.68% Decreased by -28.82% |
| Mar 31, 22 | 7.81 B Increased by +14.76% | 1.90 B Increased by +40.40% | Increased by +24.36% Increased by +22.35% |
| Dec 31, 21 | 8.00 B Increased by +7.53% | 1.73 B Decreased by -18.46% | Increased by +21.58% Decreased by -24.16% |